Amphastar Pharmaceuticals Competitors

Amphastar Pharmaceuticals (NASDAQ:AMPH) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 7.0% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and PTC Therapeutics, as reported by MarketBeat.com.

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. PTC Therapeutics has a consensus target price of $64.90, indicating a potential upside of 36.34%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and PTC Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and PTC Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.2% of Apellis Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and Apellis Pharmaceuticals, as reported by MarketBeat.com.

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Apellis Pharmaceuticals has a consensus target price of $124.6154, indicating a potential upside of 199.84%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and Apellis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Apellis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Insmed (NASDAQ:INSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and Insmed, as reported by MarketBeat.com.

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. Insmed has a consensus target price of $53.8571, indicating a potential upside of 69.90%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Amphastar Pharmaceuticals.

Profitability

This table compares Amphastar Pharmaceuticals and Insmed's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and Insmed's gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Insmed on 9 of the 14 factors compared between the two stocks.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares Amphastar Pharmaceuticals and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amphastar Pharmaceuticals and ACADIA Pharmaceuticals, as reported by MarketBeat.com.

Amphastar Pharmaceuticals currently has a consensus target price of $21.6667, indicating a potential upside of 21.11%. ACADIA Pharmaceuticals has a consensus target price of $32.7647, indicating a potential upside of 60.69%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Insider & Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Amphastar Pharmaceuticals and ACADIA Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher earnings, but lower revenue than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Reata Pharmaceuticals (NASDAQ:RETA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Amphastar Pharmaceuticals and Reata Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Amphastar Pharmaceuticals and Reata Pharmaceuticals, as reported by MarketBeat.com.

Amphastar Pharmaceuticals presently has a consensus price target of $21.6667, indicating a potential upside of 21.11%. Reata Pharmaceuticals has a consensus price target of $251.25, indicating a potential upside of 184.16%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Reata Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.

Insider and Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 64.3% of Reata Pharmaceuticals shares are held by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 31.7% of Reata Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amphastar Pharmaceuticals and Reata Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Reata Pharmaceuticals. Reata Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Reata Pharmaceuticals has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500.

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Profitability

This table compares Amphastar Pharmaceuticals and Karuna Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Amphastar Pharmaceuticals and Karuna Therapeutics, as reported by MarketBeat.com.

Amphastar Pharmaceuticals presently has a consensus price target of $21.6667, indicating a potential upside of 21.11%. Karuna Therapeutics has a consensus price target of $144.70, indicating a potential upside of 23.77%. Given Karuna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karuna Therapeutics is more favorable than Amphastar Pharmaceuticals.

Insider and Institutional Ownership

55.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are held by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are held by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Amphastar Pharmaceuticals and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amphastar Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.

Summary

Amphastar Pharmaceuticals beats Karuna Therapeutics on 8 of the 13 factors compared between the two stocks.